The article below lists barriers to entry within our field that I believe we have addressed, it's a tough game but we're on the right path:
1. Price point for the prefill is of no worry to the end user, as this is a part of the vaccine supplied. UNI are (as announced) continuing to recruit/talk to suppliers with the capabilities of mass supply to meet SA's requirements.
2. Sanofi have made sure we are capitalised, they are also paying for the intitial set-up to take us near $40m p.a in revenue.
3. Luckily we are at the shorter end of this lengthy development. We also need not worry on breaking into the market with the prefill as the product is supplied with Sanofi's vaccine. The 1ml will be the interesting part of the puzzle here, large orders would open the flood gates.
4. Patents/IP have been submitted and approved. We also continue to submit additional to protect the technology.
Yes it's been a while but I think the Sanofi deal was a strike of genius. The medical profession will have no choice but to get used to our technology, as the SA vaccines are everywhere and growing.
Article:
New Policies Evolving As Retractable Safety Syringe Suppliers Strive For Traction Published:25-May-2009
By Staff Reporter
Government policies regarding syringe needle handling and disposal continue to proliferate worldwide, fostering increased demand in the use of safety syringes with Needlestick Safety and Prevention Act in the US. Retractable syringes represent the most elegant approach to deal with the caregiver sharps risk issue by lowering the risk of user error and de-emphasizing the need for a separate sharps disposal step.
Historical retractable syringe unit growth persists to be modest, hovering in the single digits. While price points remain the single most important factor limiting market penetration, several unrelated issues are slowing the market acceptance of retractable syringes. Many contributors in this sector are undercapitalized and unprepared for the lengthy development, approval and sales cycle steps required to establish a foothold against entrenched devices, user habits, buying cycles and competitors. Patent and IP challenges are another risk area that has impacted and in some cases derailed the product plans of aspiring market entrants, while draining the financial resources of others.
Several medical sector companies are evolving their business strategies to focus on niche opportunities for which retractable safety syringes present strong business and use cases.
These developments, long overdue, signify a willingness on the part of syringe developers to accept the role of retractable syringes as a specialty device.
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)